Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02487498 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 355
- Enrollment target
NCT02487498 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 355 participants.
The verdict
NCT02487498, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 355 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining an acceptable safety profile.
Interventions
- DRUG QVA149
- DRUG Umeclidinium/vilanterol
- DRUG Placebo (QVA149)
- DRUG Placebo (umeclidinium/vilanterol )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2015-07-27 |
| Est. Completion | 2016-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02487498
The ClinicalTrials.gov registry entry for NCT02487498 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which QVA149 is the first listed.
NCT02487498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02487498 about?
NCT02487498 is a clinical study titled "Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.". The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining an acceptable safety profile.
What is the current status of trial NCT02487498?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 355 participants. The study started on 2015-07-27. Estimated completion is 2016-09-06.
What interventions are being tested in trial NCT02487498?
The interventions under investigation include: QVA149 (DRUG), Umeclidinium/vilanterol (DRUG), Placebo (QVA149) (DRUG), Placebo (umeclidinium/vilanterol ) (DRUG).
Who is sponsoring clinical trial NCT02487498?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.